Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.

Publication/Presentation Date

9-1-2007

Abstract

OBJECTIVE: Renin-angiotensin system blockade is now standard in the management of the patient with type 2 diabetes mellitus. We aimed to investigate whether high doses of valsartan, an angiotensin receptor blocker, are superior to conventional doses to reduce urinary albumin excretion rates (UAER) in such patients.

PATIENTS AND METHODS: Three hundred and ninety-one hypertensive patients with type 2 diabetes mellitus and UAER 20-700 microg/min were randomized to 160, 320 or 640 mg valsartan. All received valsartan 160 mg for the first 4 weeks. Valsartan dose was then increased in two of three groups for 30 weeks. Overnight urine collections at baseline, 4, 16, and 30 weeks in triplicate were used to assess proteinuria.

RESULTS: Comparable albuminuria reductions occurred in all groups at week 4 (P

CONCLUSION: High doses of valsartan reduced albuminuria more than the more commonly used 160 mg dose, apparently independent of blood pressure. Thus, at least in type 2 diabetes mellitus, higher doses of valsartan are required to optimize tissue protection than for blood pressure control.

Volume

25

Issue

9

First Page

1921

Last Page

1926

ISSN

0263-6352

Disciplines

Medicine and Health Sciences

PubMedID

17762658

Department(s)

Cardiology Division

Document Type

Article

Link to Full Text

Share

COinS